Rani Therapeutics Holdings, Inc. (RANI) stock
RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3039% above fair value
$0.56+0.02 (+3.54%)
Close on Nov 17, 2026Market cap $77.98MP/E –Yield –
Rani Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Rani Therapeutics's total assets was $60.84M at Jun 30, 2026. For fiscal 2025 it was $58.62M, up 60.0% from the year before. The highest annual figure on record is $124.21M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.62M | +60.0% |
| FY2024 | Dec 31, 2024 | $36.63M | -36.7% |
| FY2023 | Dec 31, 2023 | $57.92M | -46.4% |
| FY2022 | Dec 31, 2022 | $108.03M | -13.0% |
| FY2021 | Dec 31, 2021 | $124.21M | +56.4% |
| FY2020 | Dec 31, 2020 | $79.42M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $60.84M | +260.1% |
| Q1 FY2026 | Mar 31, 2026 | $51.88M | +115.0% |
| Q4 FY2025 | Dec 31, 2025 | $58.62M | +60.0% |
| Q3 FY2025 | Sep 30, 2025 | $10.14M | -76.7% |
| Q2 FY2025 | Jun 30, 2025 | $16.90M | -61.4% |
| Q1 FY2025 | Mar 31, 2025 | $24.13M | -54.9% |
| Q4 FY2024 | Dec 31, 2024 | $36.63M | -36.7% |
| Q3 FY2024 | Sep 30, 2024 | $43.54M | -38.2% |
| Q2 FY2024 | Jun 30, 2024 | $43.73M | -47.6% |
| Q1 FY2024 | Mar 31, 2024 | $53.51M | -44.5% |
| Q4 FY2023 | Dec 31, 2023 | $57.92M | -46.4% |
| Q3 FY2023 | Sep 30, 2023 | $70.44M | -34.9% |
| Q2 FY2023 | Jun 30, 2023 | $83.51M | -20.0% |
| Q1 FY2023 | Mar 31, 2023 | $96.45M | -16.4% |
| Q4 FY2022 | Dec 31, 2022 | $108.03M | -13.0% |
| Q3 FY2022 | Sep 30, 2022 | $108.20M | -21.0% |
| Q2 FY2022 | Jun 30, 2022 | $104.34M | +34.9% |
| Q1 FY2022 | Mar 31, 2022 | $115.31M | +45.2% |
| Q4 FY2021 | Dec 31, 2021 | $124.21M | – |
| Q3 FY2021 | Sep 30, 2021 | $136.96M | – |
| Q2 FY2021 | Jun 30, 2021 | $77.32M | – |
| Q4 FY2020 | Dec 31, 2020 | $79.42M | – |
See a number that looks wrong?